Catalog No.S1368 Synonyms: Etretin, RO 10-1670

For research use only.

Acitretin (Etretin, RO 10-1670) is a second generation retinoid used for psoriasis.

Acitretin Chemical Structure

CAS No. 55079-83-9

Selleck's Acitretin has been cited by 2 Publications

2 Customer Reviews

Purity & Quality Control

Choose Selective Retinoid Receptor Inhibitors

Biological Activity

Description Acitretin (Etretin, RO 10-1670) is a second generation retinoid used for psoriasis.
In vitro

Acitretin stimulates ADAM10 promoter activity with an EC(50) of 1.5 mM and leads to an increase of mature ADAM10 protein that results in a two- to three-fold increase of the ratio between alpha- and beta-secretase activity in neuroblastoma cells. [1] Acitretin (5-20 μM) impairs mitochondrial phosphorylation efficiency as demonstrated by the decrease in the state 3 respiration and ATP levels, and by the increase in the lag phase of ADP phosphorylation cycle, without affecting the membrane potential. Acitretin induces Ca(2+)-mediated mitochondrial permeability transition (MPT) and decreased the adenine nucleotide translocase (ANT) content. [2] Acitretin preferentially inhibits the growth of SCL-1 cells in a dose- and time-dependent manner, but not of non-malignant keratinocyte HaCaT cells. Acitretin increases the levels of CD95 (Fas), CD95-ligand and Fas-associated death domain. Acitretin is able to induce apoptosis in skin cancer cells possibly via death receptor CD95 apoptosis pathway without affecting the viability of normal keratinocyte. [3]

In vivo Acitretin undergoes alpha-oxidation, chain shortening O-demethylation, and glucuronidation in the perfused rat liver. [4] Acitretin rapidly appears in liver and muscle of rats, where it undergoes redistribution into skin and adipose tissue. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 326.43


CAS No. 55079-83-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04841187 Recruiting -- Psoriasis Assistance Publique - Hôpitaux de Paris|Société de Dermatologie Française September 6 2021 --
NCT04245319 Recruiting Drug: Acitretin|Other: Narrow band ultraviolet B Hyperlipidemias|Xerosis|Depression|Liver Diseases Cairo University January 1 2020 Not Applicable
NCT05203354 Completed Radiation: Narrowband Ultraviolet B|Drug: Acitretin Psoriasis Mahmoud Ahmed Ali Ahmed|Aswan University Hospital September 1 2018 Phase 4
NCT01039142 Completed Drug: Acitretin Psoriasis Postgraduate Institute of Medical Education and Research March 2008 Phase 4
NCT00488384 Withdrawn Drug: Chemopreventive application (Acitretin) Carcinoma Squamous Cell Günther Hofbauer|University of Zurich June 2007 Phase 4
NCT00156247 Completed Drug: acitretin Psoriasis University of Medicine and Dentistry of New Jersey|Connetics Corp.|Rutgers The State University of New Jersey September 2005 Phase 2

(data from, updated on 2022-11-29)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Acitretin | Acitretin ic50 | Acitretin price | Acitretin cost | Acitretin solubility dmso | Acitretin purchase | Acitretin manufacturer | Acitretin research buy | Acitretin order | Acitretin mouse | Acitretin chemical structure | Acitretin mw | Acitretin molecular weight | Acitretin datasheet | Acitretin supplier | Acitretin in vitro | Acitretin cell line | Acitretin concentration | Acitretin nmr